MDxHealth SA ADR (MDXH)

MDxHealth SA ADR is a depositary receipt representing the company’s common stock and listed on NASDAQ under the symbol MDXH. The underlying issuer, MDxHealth SA, is a commercial-stage precision diagnostics company focused on urologic testing in the United States, Europe, and other international markets. Its portfolio includes Select mdx, a non-invasive urine test for prostate cancer, Confirm mdx, a tissue-based prostate cancer test, Resolve mdx for urinary tract infection, and Genomic Prostate Score, which is used to provide genomic insight to physicians and patients. The company commercializes these products through a urology sales organization that includes direct sales representatives, strategic account managers, and regional sales managers. MDxHealth also has a collaboration with the University of Oxford related to GPS testing in the UK ProtecT trial. Founded in 2003 and headquartered in Herstal, Belgium, the company was previously known as OncoMethylome Sciences SA.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.